The Spectranetics — Spectranetics — Technical Presentation (August 2016)
21 slides from The Spectranetics's technical presentation, Aug 11, 2016
Slide 1: ILLUMENATE European Randomized Clinical Trial: 12-Month Final Results for the Stellarex DCB
ILLUMENATE European Randomized Clinical Trial: Prof. Dr. Marianne Brodmann 12-Month Final Results for the Stellarex DCB Division of Angiology, Medical University Graz, Austria On behalf of Dr. Henrik Schröder Jewish Hospital, Berlin, Germany
Slide 2: Disclosures
Disclosures • Consulting/Honoraria for – Medtronic – BARD – Spectranetics – Intact Vascular – Avinger – Soundbite Medical – Rexgenero – Biotronik – Bayer – Daiichi – Böhringer Ingelheim – Astra Zeneca
Slide 3: ILLUMENATE EU RCT Overview
ILLUMENATE EU RCT Overview Stellarex DCB vs. PTA Prospective, randomized, multi-center, trial Patients will be followed for up to 5 years Rigorous data collection process, independent adjudication by: • Angiographic Core Laboratory1 • Duplex Ultrasound Core Laboratory2 • Clinical Events Comm
Slide 4: Investigators
ILLUMENATE EU RCT Investigators Dr. Henrik Schroeder :Jewish Hospital, Berlin National Principal Investigator Prof. Marianne Brodmann: LKH University Hospital Graz Dr. Beata Lux: St Joseph Hospital, Berlin Prof. Peter Reimer:Clinical Center, Karlsruhe Dr. Dirk-Roelfs Meyer: Lutheran Hospital Hubertu
Slide 5: Objective and Primary Endpoints
Objective and Primary Endpoints ILLUMENATE EU RCT Objective: Demonstrate safety and efficacy of the Stellarex DCB vs. standard PTA for treatment of arterial disease in the SFA and/or popliteal arteries Primary Safety Endpoint: Freedom from device- and procedure- related death through 30 days and fre
Slide 6: Study Device: Stellarex DCB (Spectranetics)
Study Device: StellarexTM DCB (Spectranetics) CAUTION: Investigational device. Not for sale or distribution in the United States. EnduraCoatTM technology: • Low dose paclitaxel, 2 µg/mm2 • Excipient: Polyethylene Glycol (PEG) • Proprietary open-folded coating technology Balloon catheter features: •
Slide 7: Key Eligibility Criteria
Key Eligibility Criteria ILLUMENATE EU RCT Inclusion Criteria • Rutherford class 2, 3 or 4 • Lesion(s) located in the SFA and/or popliteal • Has at least one patent run-off below-the-knee • 1 or 2 target lesion(s) with cumulative length 3-20 cm • Target vessel reference diameter 4-6 mm Exclusion Cri
Slide 8: Trial Design
ILLUMENATE EU RCT Trial Design Patient Eligible & Consented Pre-dilatation N=328 Stent required (N=33) (BMS + Stellarex) Stent not required (N=295) Randomization (3:1) Stellarex DCB (N=222) PTA (N=72) Provisional stenting as required Post-dilatation as required Provisional stenting as required Post-
Slide 9: Baseline Patient Characteristics
Baseline Patient Characteristics ILLUMENATE EU RCT ITT data set Stellarex PTA p Age (years) 66.8 ± 9.2 (222) 69.0 ± 8.6 (72) 0.079 Male 72.1% (160/222) 68.1% (49/72) 0.514 Rutherford Clinical Category 0.525 2 15.4% (34/221) 21.1% (15/71) 3 82.8% (183/221) 77.5% (55/71) 4 1.8% (4/221) 1.4% (1/71) Dia
Slide 10: Baseline Angiographic Data
Baseline Angiographic Data ILLUMENATE EU RCT ITT Data Set: Per Core Lab Stellarex PTA p Lesion Length (cm)1 7.2± 5.2 (250) 7.1 ± 5.3 (79) 0.878 Lesion Type De Novo Restenotic 92.1% (234/254) 7.9% (20/254) 89.9% (71/79) 10.1% (8/79) 0.529 Total Occlusion 19.2% (48/250) 19.0% (15/79) 0.967 Calcificati
Slide 11: Procedural Characteristics
Procedural Characteristics ILLUMENATE EU RCT ITT data set Stellarex PTA p Pre-dilatation Performed1 100% (254/254) 98.7% (78/79) 0.237 Post-DCB/PTA Dissection Grades Grade A-C Grade D-F 61.1% (151/247) 1.2% (3/247) 74.0% (57/77) 0.0% (0/77) 0.095 Flow-limiting Dissection 0.4% (1/247) 0.0% (0/77) 1.0
Slide 12: Primary Safety Endpoint Met
Primary Safety Endpoint Met ILLUMENATE EU RCT As-Treated Data Set 1. Composite of freedom from device and procedure-related death through 30 days & freedom from target limb major amputation & CD-TLR through 395 days. Per subject, as adjudicated by the CEC. 2. Numbers are % (n/N) [Events]- Denominato
Slide 13: Key Safety Outcomes
Key Safety Outcomes ILLUMENATE EU RCT As-Treated Data Set Stellarex PTA P2 12-Month MAEs1 6.8% (14/207) [20] 18.0% (11/61) [12] 0.008 Cardiovascular Death 1.0% (2/206) [3] 1.6% (1/61) [1] 0.542 Target Limb Amputation 0.5% (1/204) [1]3 0.0% (0/60) [0] >0.999 Clinically-Driven TLR 5.9% (12/205) [16] 1
Slide 14: Primary Efficacy Endpoint Met
Primary Efficacy Endpoint Met ILLUMENATE EU RCT Stellarex PTA Difference [95% CI] P-value Primary Patency at 12 months1 ITT Data Set 83.9% (188/224) [78.5, 88.5] 60.6% (40/66) [47.8, 72.4] 23.3% [10.6%, 36.1%] P<0.001 As-Treated Data Set 83.9% (188/224) [78.5, 88.5] 61.5% (40/65) [48.6, 73.3] 22.4%
Slide 15: Primary Patency at 12 Months
Primary Patency at 12 Months: 89.0% ILLUMENATE EU RCT ITT Data Set P<0.001 by log-rank test 65.0% @ day 365 Primary patency is defined as freedom from restenosis (determined by duplex ultrasound PSVR threshold of 2.5) and freedom from clinically-driven TLR at 12 months. Assessed per lesion. KM estim
Slide 16: CD-TLR Free at 12 Months
CD-TLR1 Free at 12 Months: 94.8% ILLUMENATE EU RCT ITT3 Data Set 1. Clinically-driven TLR defined as reintervention due to PSVR≥2.5 (or >50% stenosis via angio) due to an increase in the RCC >1 category or deterioration in the ABI by >0.15 compared to maximum early post-procedural level. Per subject
Slide 17: Key Secondary Endpoints
Key Secondary Endpoints ILLUMENATE EU RCT ITT Data Set Percent of Subjects with Improvements at 12 Months vs. Baseline Similar outcomes at 12 months, with almost 3x greater rate of reintervention in the PTA arm.1 1. CD-TLR rate in the Stellarex arm = 5.9% vs. 16.7% in the PTA arm 2. Data derived f
Slide 18: Consistent Patency Rates Observed across 3 Studies
89.0% 89.5% 86.5% ILLUMENATE EU RCT N=222 ILLUMENATE FIH N=50 ILLUMENATE Global Interim Data N=220 Consistent Patency Rates Observed across 3 separate studies with Stellarex Kaplan-Meier estimates at day 365 shown 1. H. Schroeder et al. Catheter Cardiovasc Interv. 86:278-286 (2015). 2. P. Krishnan o
Slide 19: Data in Context: 12-Month Patency Rates
89.0% 65.0% 89.8% 66.8% 73.5% 56.8% Stellarex 2 µg/mm PTA IN.PACT Admiral 3.5 µg/mm PTA Lutonix 2 µg/mm PTA Data in Context with Core Lab* Adjudicated 12-Month Patency Rates ILLUMENATE EU-RCT IN.PACT SFA1 LEVANT 2 2 1. Tepe G. Oral presentation . Charing Cross. April 5–8, 2014. London, UK, 2014. 2.
Slide 20: Data in Context: Clinically-Driven TLR at 12 Months
5.9% 16.7% 2.4% 20.6% 12.3% 16.8% Stellarex 2µg/mm PTA IN.PACT Admiral 3.5 µg/mm PTA Lutonix 2µg/mm PTA Data in Context: Clinically-Driven TLR at 12 Months ILLUMENATE EU-RCT IN.PACT SFA1 LEVANT 22 1. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal a
Slide 21: Conclusions
Conclusions • This robust randomized study confirms First-in- Human study results • Primary safety and efficacy endpoints met and superiority was demonstrated • Stellarex is a low-dose DCB with consistently positive results – Primary Patency= 89.0% at day 365 – Freedom from CD-TLR= 94.8% at day 365